Press release
Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc
DelveInsight's "Metastatic Triple Negative Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 report offers an in-depth understanding of the Metastatic Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).
To Know in detail about the Metastatic Triple Negative Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic Triple Negative Breast Cancer Market Forecast [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Metastatic Triple Negative Breast Cancer Market Report:
*
The APAC Metastatic Triple Negative Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
In June 2024, AstraZeneca faced a setback when its leading breast cancer treatment, Truqap (capivasertib), failed to show an improvement in overall survival (OS) in a Phase III trial for triple-negative breast cancer (TNBC). The combination of Truqap and chemotherapy (paclitaxel) in the Phase III CAPItello-290 trial did not meet its dual primary endpoints, which aimed to improve OS compared to chemotherapy and placebo, either in the overall trial population or in a subgroup of patients with tumors showing specific biomarker alterations (PIK3CA, AKT1, or PTEN).
*
In June 2024, G1 Therapeutics revealed the topline results from the final overall survival (OS) analysis of its Phase III PRESERVE 2 trial, which assessed the efficacy and safety of trilaciclib given before chemotherapy (gemcitabine and carboplatin; GCb) in patients with metastatic triple-negative breast cancer (TNBC).
*
In February 2024, Carrick Therapeutics announced that the first patient has been administered the treatment in its Phase Ib/II clinical trial, which is evaluating the combination of samuraciclib (CT7001) in women with estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer.
*
In February 2024, Arvinas announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) as a monotherapy for treating adults with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer that has previously been treated with endocrine-based therapy.
*
Key Metastatic Triple Negative Breast Cancer Companies: AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others
*
Key Metastatic Triple Negative Breast Cancer Therapies: Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others
*
The Metastatic Triple Negative Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic Triple Negative Breast Cancer pipeline products will significantly revolutionize the Metastatic Triple Negative Breast Cancer market dynamics.
Metastatic Triple Negative Breast Cancer Overview
Metastatic Triple Negative Breast Cancer (mTNBC) is an aggressive and advanced form of breast cancer that is characterized by the absence of three key receptors - estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers, and when it progresses to the metastatic stage, it poses significant challenges in terms of treatment and prognosis.
Get a Free sample for the Metastatic Triple Negative Breast Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast [https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Metastatic Triple Negative Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Metastatic Triple Negative Breast Cancer Epidemiology Segmentation:
The Metastatic Triple Negative Breast Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:
*
Total Prevalence of Metastatic Triple Negative Breast Cancer
*
Prevalent Cases of Metastatic Triple Negative Breast Cancer by severity
*
Gender-specific Prevalence of Metastatic Triple Negative Breast Cancer
*
Diagnosed Cases of Episodic and Chronic Metastatic Triple Negative Breast Cancer
Download the report to understand which factors are driving Metastatic Triple Negative Breast Cancer epidemiology trends @ Metastatic Triple Negative Breast Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Metastatic Triple Negative Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Triple Negative Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic Triple Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic Triple Negative Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Metastatic Triple Negative Breast Cancer Therapies and Key Companies
*
LY3023414: Eli Lilly and Company
*
Niraparib: Tesaro, Inc.
*
Pembrolizumab: Merck Sharp & Dohme LLC
*
Sacituzumab Govitecan: Gilead Sciences
*
NBE-002: NBE-Therapeutics AG
*
L-NMMA: Novartis Pharmaceuticals
*
Imprime PGG : HiberCell
*
TECENTRIQ: Hoffmann-La Roche
*
IPI-549: Infinity Pharmaceuticals
*
Leronlimab (PRO 140): CytoDyn
*
MDNA11: Medicenna Therapeutics
*
ASTX727: Astex Pharmaceuticals, Inc.
*
AG-01: A&G Pharmaceutical Inc.
*
ZEN003694: Zenith Epigenetics
*
AL101: Ayala Pharmaceuticals, Inc.
*
PMD-026: Phoenix Molecular Designs
*
CDX-1140: Celldex Therapeutics
Discover more about therapies set to grab major Metastatic Triple Negative Breast Cancer market share @ Metastatic Triple Negative Breast Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Metastatic Triple Negative Breast Cancer Market Report
*
Study Period: 2020-2034
*
Coverage: APAC (India, China, South Korea, Taiwan, and Australia)
*
Key Metastatic Triple Negative Breast Cancer Companies: AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others
*
Key Metastatic Triple Negative Breast Cancer Therapies: Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others
*
Metastatic Triple Negative Breast Cancer Therapeutic Assessment: Metastatic Triple Negative Breast Cancer current marketed and Metastatic Triple Negative Breast Cancer emerging therapies
*
Metastatic Triple Negative Breast Cancer Market Dynamics: Metastatic Triple Negative Breast Cancer market drivers and Metastatic Triple Negative Breast Cancer market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Metastatic Triple Negative Breast Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic Triple Negative Breast Cancer Market Access and Reimbursement
To know more about Metastatic Triple Negative Breast Cancer companies working in the treatment market, visit @ Metastatic Triple Negative Breast Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-tnbc-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Metastatic Triple Negative Breast Cancer Market Report Introduction
2. Executive Summary for Metastatic Triple Negative Breast Cancer
3. SWOT analysis of Metastatic Triple Negative Breast Cancer
4. Metastatic Triple Negative Breast Cancer Patient Share (%) Overview at a Glance
5. Metastatic Triple Negative Breast Cancer Market Overview at a Glance
6. Metastatic Triple Negative Breast Cancer Disease Background and Overview
7. Metastatic Triple Negative Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic Triple Negative Breast Cancer
9. Metastatic Triple Negative Breast Cancer Current Treatment and Medical Practices
10. Metastatic Triple Negative Breast Cancer Unmet Needs
11. Metastatic Triple Negative Breast Cancer Emerging Therapies
12. Metastatic Triple Negative Breast Cancer Market Outlook
13. Country-Wise Metastatic Triple Negative Breast Cancer Market Analysis (2020-2034)
14. Metastatic Triple Negative Breast Cancer Market Access and Reimbursement of Therapies
15. Metastatic Triple Negative Breast Cancer Market Drivers
16. Metastatic Triple Negative Breast Cancer Market Barriers
17. Metastatic Triple Negative Breast Cancer Appendix
18. Metastatic Triple Negative Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-triple-negative-breast-cancer-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-astrazeneca-bioeclipse-therapeutics-precigen-inc-clovis-oncology-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc here
News-ID: 3790277 • Views: …
More Releases from ABNewswire
Willow Creek Coffee Company Pioneers Roast-to-Order Model Bringing Cafe Quality …
Artisan coffee roaster Willow Creek Coffee Company launches nationwide delivery of freshly roasted beans sourced globally and roasted upon order. The sustainable business model builds community around exceptional coffee while revolutionizing freshness standards in specialty coffee.
Willow Creek Coffee Company emerges in the competitive specialty coffee landscape with a compelling proposition that prioritizes freshness, quality, and community building over conventional retail distribution models. The company's launch at willowcreekcoffeecompany.com introduces coffee lovers…
New analysis reveals why leading B2B companies dominate ChatGPT search results
After analyzing over 800,000 AI citations, marketing expert Sebastian Ocampo reveals why 89% of B2B buyers now use AI to research vendors and why most companies remain invisible. New data shows competitor blogs outperform traditional sources 56% of the time in ChatGPT results. Ocampo shares his five-step framework for capturing AI search visibility before your market gets locked out by early movers.
SWITZERLAND - Oct 31, 2025 - According to Sebastian…
Astral Signature Revolutionizes Sustainable Fashion with Mindfulness-Inspired De …
New lifestyle brand Astral Signature combines print-on-demand technology with astrology and self-growth themes to serve conscious consumers across North America. The company's expansion includes Amazon launch and exclusive 2026 World Cup collections targeting purpose-driven fashion seekers.
Astral Signature establishes itself as a pioneering force in conscious fashion following its 2025 launch that brings mindfulness-inspired apparel to intentional consumers throughout the United States, Mexico, and Canada. The brand's rapid expansion across astralsignature.com,…
Quest Auto Sales Transforms Used Cars for Sale Market with a Customer-First Fina …
Quest Auto Sales at 4501 L St, Omaha, offers flexible financing and transparent pricing on pre-owned vehicles, driving growth through customer referrals and personalized service in the local market.
The pre-owned vehicle market in Omaha is shifting as Quest Auto Sales [https://www.questautosales.com/] introduces a financing approach that prioritizes customer needs over rigid sales quotas. Located at 4501 L St in Omaha, NE 68117, the dealership has built its reputation on flexible…
More Releases for Triple
HuxQ10 Relaunches with New Triple Approval
Huxley Europe is celebrating the relaunch of its HuxQ10 capsules, and is delighted to announce that they are approved Halal by Halal Trust, approved Kosher and certified vegan. Three reasons to celebrate!
Coenzyme Q10, also known as Ubiquinone or simply Q10, is a vitamin like substance that occurs naturally in the body. The first recognised role of CoQ10 was in mitochondrial biogenetics, where it plays a central role in…
Triple Net Lease Properties And Tenants
Aug 26, 2019 - A triple net or NNN lease is a single-tenant arrangement that requires the tenant to pay all operating expenses associated with the property they've rented. NNN investors enjoy a regular flow of income without any liabilities as all additional expenses are covered by the tenant. This kind of investment is suitable for investors who don't want to spend time and money in the maintenance of their…
TRIPLE TRIPADVISOR SUCCESS FOR ANOKI RESTAURANT
Anoki has reinforced its reputation as one of the UK’s leading fine dining restaurants after all three restaurants were inducted into TripAdvisor’s coveted Hall of Fame.
The restaurants in Derby, Nottingham and Burton have received the accolade after being awarded the prestigious Certificate of Excellence for five consecutive years.
Now in its ninth year, The TripAdvisor Certificate of Excellence celebrates hospitality businesses that are consistently excellent – having earned great traveller reviews…
Triple award winning awning model
Cassette awning markilux 970 now also awarded iF Design Award
In autumn, last year, awning expert markilux already enjoyed the success of its new cassette awning, the markilux 970. Already in the first year it managed to receive two design awards. At the beginning of 2014 a third award followed: the internationally renowned iF Design Award. More than 5,000 registrations from 59 countries participated in the competition in 2016.
According to…
Panthong Manichanh Launches Triple M Designz
FOR IMMEDIATE RELEASE
Panthong Manichanh Launches Triple M Designz
Triple M Designz to provide videography, multimedia and graphic arts services to musicians, entertainers and entrepreneurs.
San Diego, California, August 23, 2011 Panthong Manichanh today announced the launch of Triple M Designz. Triple M Designz will provide a unique combination of video production, graphic design, photography, and promotional art, ranging from designing logos, developing brands, designing album cover, and filming and producing videos for…
Triple Diamond Energy Corp. Begins Triple Diamond Energy No. 2 Joint Venture
Triple Diamond Energy Corp., a Texas-based independent oil and gas drilling company, is currently preparing to drill the No. 2 Joint Venture oil project.
ADDISON, TX -- Texas-based oil and gas exploration and production company, Triple Diamond Energy Corp., has announced that it is now in the planning stages of the Triple Diamond Energy No. 2 Joint Venture oil well project. The project consists of plans to drill four development wells.…
